Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo’s FLT3 Inhibitor Grabs FDA’s Breakthrough Therapy Status
Daiichi Sankyo said on August 1 that the FDA designated its FLT3 inhibitor quizartinib as a Breakthrough Therapy for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). The designation is based on a global PIII trial,…
To read the full story
Related Article
- EMA Accepts Quizartinib Application, with Accelerated Assessment Status: Daiichi Sankyo
November 7, 2018
- Daiichi Sankyo Files Quizartinib for AML in Japan
October 18, 2018
BUSINESS
- NEC Bio, Transgene Strike Licensing Deal for Cancer Vaccine
April 6, 2026
- Expert Highlights Subcutaneous Benefits of Rybrofaz in Lung Cancer
April 6, 2026
- Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
- Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…